Monsanto Secures FDA Approval for its Biological Corn Seed Treatment
Monsanto has secured approval from the U.S. Food and Drug Administration (FDA) for its biological seed treatment developed to strengthen symbiosis between microbes and corn plants resulting in stronger root systems.
A stronger root system results in greater efficiency in nutrient uptake, and reduces the release of nutrients into the environment. The greater plant biomass also provides a higher level of carbon sequestration in the soil, and the absorption of more carbon dioxide from the air.
Under the project, Corn Bio Yield 2, a collaboration between Monsanto and Novozymes, Acceleron B-360 ST will be used in conjunction with Acceleron B-300, which was released last year, by farmers on four million acres in its first year of release.
Acceleron B-360 ST is scheduled to be released in the U.S. and Canada in 2019, which will then be followed by selective releases in certain EU and Middle East countries pending approval.